Most bought healthcare stocks in Q2 2020

See which Healthcare stocks institutional investors increased the most in Q2 2020, measured as net growth in reported share positions from Q1 2020 into Q2 2020. Notable additions at the top of this list include CERUS CORP (CERS), ENVISTA HOLDINGS CORP (NVST), ABBVIE INC (ABBV), ZENTALIS PHARMACEUTICALS INC (ZNTL). These rankings are based on SEC 13F filings from the investors we track.

SymbolNameNet sharesNet valueNewAddedTrimmedSold outHolding now
CERSCERUS CORP7,753,379$78.48K01001
NVSTENVISTA HOLDINGS CORP7,181,637$172.91K11002
ABBVABBVIE INC5,666,815$864.56K235011
ZNTLZENTALIS PHARMACEUTICALS INC4,443,284$213.37K10001
MCRBSERES THERAPEUTICS INC4,148,123$31.32K02002
PACBPACIFIC BIOSCIENCES OF CALIF4,038,433$15.63K01002
IOVAIOVANCE BIOTHERAPEUTICS INC3,348,094$89.70K01001
EXELEXELIXIS INC2,927,494$200.60K01102
HCAHCA HEALTHCARE INC2,488,704$274.54K14005
ABTABBOTT LABORATORIES2,404,733$452.60K22218
EDITEDITAS MEDICINE INC2,010,226$119.42K01203
WBAWALGREENS BOOTS ALLIANCE INC1,905,073$79.94K13015
VCYTVERACYTE INC1,797,934$51.76K01001
TMOTHERMO FISHER SCIENTIFIC INC1,667,522$725.33K12619
AMRNAMARIN CORP PLC -ADR1,449,260$17.10K01002
INCYINCYTE CORP1,423,735$425.51K02113
EHCENCOMPASS HEALTH CORP1,330,331$78.91K03003
CLLSCELLECTIS - ADR1,231,281$35.23K01001
TAKTAKEDA PHARMACEUTIC-SP ADR1,211,314$38.05K01102
NTLAINTELLIA THERAPEUTICS INC1,205,093$115.33K11002
TWSTTWIST BIOSCIENCE CORP999,397$54.75K01001
PSNLPERSONALIS INC964,618$17.92K01001
XRAYDENTSPLY SIRONA INC903,580$96.60K11214
SYKSTRYKER CORP865,914$263.23K05015
TEVATEVA PHARMACEUTICAL-SP ADR854,385$271.91K02115
NVONOVO-NORDISK A/S-SPONS ADR854,237$203.04K21003
EXASEXACT SCIENCES CORP821,717$144.57K01102
EWEDWARDS LIFESCIENCES CORP786,408-$167.30K05035
ZTSZOETIS INC767,099$409.63K23217
NBIXNEUROCRINE BIOSCIENCES INC765,382$118.88K01001
MNKDMANNKIND CORP762,715$1.33K10001
SUPNSUPERNUS PHARMACEUTICALS INC690,600$21.60K01001
GMABGENMAB A/S -SP ADR666,012$37.42K01203
TGTXTG THERAPEUTICS INC643,600$17.47K01001
INVAINNOVIVA INC632,894$30.94K02002
PDCOPATTERSON COS INC624,775$16.06K01102
CORTCORCEPT THERAPEUTICS INC617,155$51.31K01001
TXG10X GENOMICS INC-CLASS A615,653$55.27K11002
HALOHALOZYME THERAPEUTICS INC613,753$33.73K01203
DXCMDEXCOM INC573,293$361.64K11002
REGNREGENERON PHARMACEUTICALS525,662$627.18K02022
CDNACAREDX INC487,358$27.99K01001
CLDXCELLDEX THERAPEUTICS INC466,988$19.34K01001
FATEFATE THERAPEUTICS INC464,748$22.66K01001
HSICHENRY SCHEIN INC434,257$36.45K12104
CLSDCLEARSIDE BIOMEDICAL INC418,550$85801001
BDXBECTON DICKINSON AND CO417,662$197.73K154110
PCRXPACIRA BIOSCIENCES INC382,655$66.82K01001
VNDAVANDA PHARMACEUTICALS INC380,168$8.51K01001
PBYIPUMA BIOTECHNOLOGY INC377,100$6.10K01001
20 symbols with net change in reported shares from tracked managers.0.002.1M4.3M6.4M8.5MNet change in reported shares (tracked managers)CERSNVSTABBVZNTLMCRBPACBIOVAEXELHCAABTEDITWBAVCYTTMOAMRNINCYEHCCLLSTAKNTLASymbol

Frequently asked questions about Most bought healthcare stocks in Q2 2020

  • What are the most bought Healthcare stocks in Q2 2020?

    The most bought healthcare stocks in Q2 2020 are those with the largest increase in reported share counts across tracked institutional investors compared to Q1 2020, based on SEC 13F filings.

  • Which healthcare stocks did institutional investors added to the most in Q2 2020?

    Among the managers we track, net additions were largest in companies such as CERUS CORP (CERS), ENVISTA HOLDINGS CORP (NVST), ABBVIE INC (ABBV), based on aggregated 13F data.

  • How is institutional buying calculated?

    Buying is calculated by summing the net increase in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q1 2020).

  • Does this include all institutional owners?

    These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.

  • Are these trades real-time?

    No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.